The severity of ALS correlates with how badly mutations destabilize superoxide dismutase 1, and promote its aggregation, according to a new study.
By beaming red light at a blood sample and measuring the scattered photons, scientists claim to identify people with Alzheimer’s disease.
Two trials suggest that a fixed combination of a cough medicine and a cardiac arrhythmia medicine might treat agitation and quiet emotional outbursts in people with Alzheimer’s.
People with moderate to severe Alzheimer’s have higher levels of orexin, a neuropeptide that keeps people awake, a study reports. The findings solidify links between orexin and sleep disturbances associated with the disease.
Aβ oligomers rapidly seed tau pathology in macaques, potentially providing a model for drug testing that better reflects human pathology.Aβ oligomers rapidly seed tau pathology in macaques, potentially providing a model for drug testing that better reflects human pathology.
Using a rarely implemented in vitro fertilization procedure, a woman whose family carries a presenilin mutation delivered twins who are virtually assured of escaping early onset Alzheimer’s disease.
Introducing a clinical trials database for ALS that encompasses nearly 9,000 patient records, the organizers tease with the first few findings.
Amyloid plaques and tau tangles sprout in human neuron cultures grown in a supportive gel. Researchers think this system may closely model human disease and aid in drug discovery.
At the 139th meeting of the American Neurological Association, held October 12-14 in Baltimore, scientists explained some of the newest therapies, preventative techniques, and diagnostic tests that may help control Alzheimer’s disease. An in vitro fertilization procedure has helped one woman who has early-onset Alzheimer’s in her family conceive twins with normal copies of the presenilin 1 gene. On the therapeutics front, a drug that is FDA-approved to quell uncontrollable laughing and crying reduced emotional outbursts and calmed patients with Alzheimer’s and other dementias. In addition, scientists reported that Raman spectroscopy of the blood might distinguish people with AD from healthy peers and people with other dementias.
Given that drugs that looked promising in Alzheimer mice have failed in human trials, is it time to find a better model? A new report claims that middle-aged macaque monkeys rapidly developed key features of AD, including neurofibrillary tangles, when Aβ oligomers were injected into their brains. Some researchers think these primates might provide a clearer picture of how AD therapeutics will perform in people.
Every month about 1,500 scientists check our jobs postings for positions in Alzheimer’s disease research and related fields. This resource is free for all. For more information, or to submit your job description, visit our jobs database.
Imagers, get your data ready! Organizers of the ninth annual Human Amyloid Imaging meeting will review abstracts submitted between October 20 and November 14 this year. The meeting will be held January 14–16, 2015, in Miami. Registration is now open. Find further details and instructions for submitting abstracts at the conference website.
- Lon Schneider on A New Drug to Calm Agitation, Uncontrollable Laughing and Crying, in Alzheimer’s?
- Henrietta Nielsen on Wake Up and Smell the … Orexin? Peptide Percolates in Alzheimer’s Brain
- Brendan Lucey on Wake Up and Smell the … Orexin? Peptide Percolates in Alzheimer’s Brain
- Tara Spires-Jones on Alzheimer’s in a Dish? Aβ Stokes Tau Pathology in Third Dimension
- Sanjay Pimplikar on Alzheimer’s in a Dish? Aβ Stokes Tau Pathology in Third Dimension
- Fred Van Leuven on Alzheimer’s in a Dish? Aβ Stokes Tau Pathology in Third Dimension
- Samira Saadi on Evidence Mounts That Mitochondrial Gene Is Bona Fide ALS, FTD Risk Factor